Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction (ESCAPE)
Efficiency in Management of Organ Dysfunction Associated With Infection by the Novel SARS-CoV-2 Virus (COVID-19) Through a Personalized Immunotherapy Approach: the ESCAPE Clinical Trial
Sponsor: Hellenic Institute for the Study of Sepsis
Listed as NCT04339712, this PHASE2 trial focuses on COVID-19 and Corona Virus Infection and remains completed. Sponsored by Hellenic Institute for the Study of Sepsis, it has been updated 6 times since 2020, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Feb 2021 — Jul 2024 [monthly]
Completed PHASE2
Status: Recruiting → Completed
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE2
▶ Show 1 earlier version
-
May 2020 — Jan 2021 [monthly]
Recruiting PHASE2
First recorded
Apr 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hellenic Institute for the Study of Sepsis
For direct contact, visit the study record on ClinicalTrials.gov .